2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid | 1380547-64-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
• CAS: 1380547-64-7
• 化学式: C₂₁H₁₇NO₃
• 分子量: 331.371
• InChiKey: CSVZMMIIUIOJRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid 在 氨 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 生成 2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
  参考文献：
  名称：

  Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists

  摘要：

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.023
• 作为产物：
  描述：

  1-萘甲酰氯 在 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists

  摘要：

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.023

文献信息

• [EN] MODULATORS OF REV-ERB<br/>[FR] MODULATEURS DE REV-ERB
  申请人：KAMENECKA THEODORE MARK

  公开号：WO2013033310A1

  公开（公告）日：2013-03-07

  The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, or an autoimmune disorder.
• Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists
  作者：Romain Noel、Xinyi Song、Youseung Shin、Subhashis Banerjee、Douglas Kojetin、Li Lin、Claudia H. Ruiz、Michael D. Cameron、Thomas P. Burris、Theodore M. Kamenecka

  DOI：10.1016/j.bmcl.2012.04.023

  日期：2012.6

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.